Hostname: page-component-78c5997874-8bhkd Total loading time: 0 Render date: 2024-11-19T03:57:33.712Z Has data issue: false hasContentIssue false
  • English
  • Français

Ending choose-your-own-adventure care for agitation in dementia

Published online by Cambridge University Press:  23 June 2022

Donovan T. Maust Open the ORCID record for Donovan T. Maust [Opens in a new window]
Donovan T. Maust*
Affiliation:
Department of Psychiatry, University of Michigan, Ann Arbor, MI, USA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, MI, USA Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA
*
Email: maustd@umich.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Commentary
Information
International Psychogeriatrics , Volume 34 , Special Issue 10: Issue Theme: Pharmacotherapy for Serious Neuropsychiatric Disorders , October 2022 , pp. 867 - 869
Copyright
© International Psychogeriatric Association 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Baillon, S. F., Narayana, U., Luxenberg, J. S. and Clifton, A. V. (2018). Valproate preparations for agitation in dementia. Cochrane Database of Systematic Reviews, 10, CD003945.Google ScholarPubMed
Davies, S. J. C. et al. (2018). Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia. Journal of Psychopharmacology, 32, 509–523.CrossRefGoogle ScholarPubMed
Geda, Y. E. et al. (2008). Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: population-based study. Archives of General Psychiatry, 65, 1193–1198.Google ScholarPubMed
Harris, D. A. et al. (2022). Potential unintended consequences of antipsychotic reduction in Ontario nursing homes. Journal of the American Medical Directors Association, 23, 1066–1072.e7.CrossRefGoogle ScholarPubMed
Jester, D. J., Molinari, V., Zgibor, J. C. and Volicer, L. (2021). Prevalence of psychotropic polypharmacy in nursing home residents with dementia: a meta-analysis. International Psychogeriatrics, 33, 1083–1098.CrossRefGoogle ScholarPubMed
Kales, H. C., Gitlin, L. N. and Lyketsos, C. G. (2015). Assessment and management of behavioral and psychological symptoms of dementia. BMJ, 350, h369.CrossRefGoogle ScholarPubMed
Kumar, S. et al. (2022). Impact of standardizing care for agitation in dementia using an integrated care pathway on an inpatient geriatric pyschiatry unit. International Pyschogeriatrics, 34, 919–928. DOI 10.1017/S1041610222000321.CrossRefGoogle Scholar
Lei, L., Samus, Q. M., Thomas, K. S. and Maust, D. T. (2022). Medication costs and use of older Americans in assisted living settings: a nationally representative cross-sectional study. Journal of General Internal Medicine, 1–8. DOI 10.1007/s11606-022-07434-3.Google ScholarPubMed
Lyketsos, C. G. et al. (2011). Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimer’s & Dementia, 7, 532–539.CrossRefGoogle ScholarPubMed
Maust, D. T. et al. (2021). Prevalence of central nervous system-active polypharmacy among older adults with dementia in the United States. JAMA, 325, 952–961.CrossRefGoogle Scholar
Maust, D. T., Kim, H. M., Chiang, C. and Kales, H. C. (2018). Association of the Centers for Medicare & Medicaid Services’ national partnership to improve dementia care with the use of antipsychotics and other psychotropics in long-term care in the United States from 2009 to 2014. JAMA Internal Medicine, 178, 640–647.CrossRefGoogle ScholarPubMed
Mega, M. S., Cummings, J. L., Fiorello, T. and Gornbein, J. (1996). The spectrum of behavioral changes in Alzheimer’s disease. Neurology, 46, 130–135.CrossRefGoogle ScholarPubMed
Moore, T. J. and Mattison, D. R. (2017). Adult utilization of psychiatric drugs and differences by sex, age, and race. JAMA Internal Medicine, 177, 274–275.CrossRefGoogle Scholar
Okura, T. and Langa, K. M. (2011). Caregiver burden and neuropsychiatric symptoms in older adults with cognitive impairment: the Aging, Demographics, and Memory Study (ADAMS). Alzheimer Disease & Associated Disorders, 25, 116–121.CrossRefGoogle Scholar
Olivieri-Mui, B. L., Devlin, J. W., Ochoa, A., Schenck, D. and Briesacher, B. (2018). Perceptions vs. evidence: therapeutic substitutes for antipsychotics in patients with dementia in long-term care. Aging & Mental Health, 22, 544–549.CrossRefGoogle ScholarPubMed
Stern, Y. et al. (1997). Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA, 277, 806–812.CrossRefGoogle ScholarPubMed
Yaffe, K. et al. (2002). Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA, 287, 2090–2097.CrossRefGoogle ScholarPubMed